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NIPTThe development of next-generation sequencing (NGS) technology has made DNA sequencing not only rapid
and cost-effective, but also highly accurate and reproducible. The translational utility of genomic sequencing
is clear, from understanding of human genetic variation and its association with disease risk and individual
response to treatment, to the interpretation and translation of the data for clinical decision making. It will
be a critical technology for disease characterization and monitoring in molecular pathology and is expected
to become a central piece of routine healthcare management which will result in accurate and reliable
reporting, a prerequisite for physicians to practice genomic medicine.
© 2013 Elsevier Inc. All rights reserved.The development of next-generation sequencing (NGS) technol-
ogy has made DNA sequencing not only rapid and cost-effective,
but also highly accurate and reproducible. A variety of NGS-based
platforms have made translational applications feasible, including:
1) whole-genome sequencing (WGS) to detect variations across the
entire genome [1]; 2) whole-exome sequencing (WES) to identify vari-
ants in the coding regions with particular utility in cancer to detect
actionable somatic variants [2], and in genetics to efﬁciently detect the
vastmajority ofMendelian disorder variants; 3)whole-transcriptome se-
quencing, a functional manifest of genomic aberrations such as expres-
sion of variant transcripts, fusion genes, and allele-speciﬁc expression;
4) targeted sequencing of speciﬁc gene panels and/or well-deﬁned path-
ways; and 5) DNA methylation analysis, a molecular proﬁle of a com-
ponent of the epigenome with applicability in deﬁning interactions
between genomic and environmental conditions. These advances have
increased the utility of sequencing, with applications ranging from the
continued understanding of human genetic variation and its association
with disease risk and individual response to treatment, to the identiﬁca-
tion of rare diseases and the detection of chromosomal abnormalities in
maternal–fetal medicine. The demonstration of clinical utility in repro-
ductivemedicine has seen the American College of Obstetricians and Gy-
necologists (ACOG), in their Committee Opinion No. 545, recommending
non-invasive prenatal testing (NIPT) utilizing NGS for fetal aneuploidy
[3]. Efforts involving deep sequencing and circulating free tumor DNA
in the oncology space is also trending toward clinical utility [4]. Concur-
rent nuclear and mitochondrial genome sequencing may have utility inrights reserved.mitochondrial diseases [Dinwiddie et al., current issue] as well. In infec-
tious diseases, promising clinical applications include comprehensive
pathogen, virulence, and resistance factor identiﬁcation using genome
and transcriptome interrogation; one examplewould be rapid taxonomic
and strain typing studies to assist outbreak investigations [5]. Using se-
quencing to guide clinical decision-making is informationally complex,
as it involves building connections betweengenetic information in the bi-
ological realm, and treatment information in the clinical realm. Therewill
be challenges to overcome, such as consensus on medically relevant ge-
nomic variants, reimbursement for genomics-driven interventions, bur-
den on patients and clinicians of reporting, intervening, and follow-up
of genomic ﬁndings, including incidental ﬁndings [6]. Information sys-
tems can help with these problems, by supporting communication and
tracking theworkﬂow, and by smoothing the representationmismatches
between genomic and clinical information; there will be key infrastruc-
ture needs, including accessible knowledge bases capturing sequence
variants and their phenotypic associations, allowing cataloging of action-
able variants [Watt et al., current issue].
Because cancer is a disease of the genome, deciphering the genetic
makeup of a cancer can improve our diagnostic, prognostic, and tailored
therapeutic strategies. Numerous large-scale genome-wide sequencing
initiatives at individual labs [7,8] and consortia [9,10] have been under-
taken to better understand the genetics of cancer. Whole-genome,
whole-exome, and targeted sequencing (“actionable” gene panels)
have all been utilized to detect somaticmutations and characterize path-
ogenesis [6]. Custom capture panels, ranging from tens to hundreds of
clinically actionable cancer genes for targeted cancer sequencing are
available. Pre-analytical variables, including specimen types, such as
formalin-ﬁxed parafﬁn-embedded tissue, limited specimen quantities
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cells, are focus areas of current research and development to further the
application of NGS technology. As NGS capabilities rapidly advance, the
technologywill soon allow for interrogation, characterization, and even-
tually diagnosis based on the recognized and critical phenomena of spa-
tial and temporal heterogeneity of neoplastic processes. These analytical
targetsmay include selected cellswithin a tumor, circulating tumor cells,
tumor stem cells, as well as “liquid biopsies” such as circulating free
tumor nucleic acids, and circulating nano- and microvesicle-associated
nucleic acids [11–13].
Even though current practices in personalized oncology tailor ther-
apy to themutations found in each tumor due to spatial heterogeneity,
future work would not only address the dynamic nature of the cancer
due to the genetic, epigenetic, and transient gene expression changes,
including microRNAs, but also take into account the convergence and
divergence of drivermutations within the same tumor [14]. There will
be a need to develop complementary back-end solutions to better pre-
dict tumor states, consider minor sub-clones and the overall dynamics
of the heterogeneity. Developing methods for producing accurate
cell-speciﬁc proﬁles of single cells would have to be considered, such
as the robust analysis of genetic alternations and RNA/protein expres-
sion changes. Beyond static analysis, real-time analysis will be neces-
sary to fully understand the complexity of gene regulation due to the
dynamic nature of the processeswithin cancers. In addition, the ability
to co-analyze variation and phenotypic data will be critical for gener-
ating reliable inferences about disease-causing alleles, genotype–
phenotype correlations, and both gene–gene and gene–environment
interactions [15].
A second area where NGS has shown translational utility is in the
area of rare Mendelian diseases. One example of this application is the
use of exome sequencing to identify the causative gene for rare dis-
eases. Shendure et al. found the genetic basis of Kabuki syndrome,
demonstrating the power of NGS to understand these rare diseases
even with a small sample size [16]. Furthermore, there have been a
handful of cases where sequencing resulted in therapeutic options.
One of the earliest such example was the case of Nicholas Volker.
After computational ﬁltering and bioinformatics analysis of the ge-
nome of this patient, the most promising suspect was XIAP, a gene as-
sociated with inﬂammatory bowel disease, and the patient received a
bone marrow transplant as a result of this ﬁnding. Another example is
the Beery twins who were initially diagnosed with cerebral palsy and
then dopa-responsive dystonia (DRD). They were ﬁrst treated with
L-dopa; however, as the effects wore off, whole genome sequencing
identiﬁed deleterious mutations in the sepiapterin reductase (SPR)
gene and supplemental 5-hydroxytryptophan (5-HTP) was given as
it was known that SPR affected the pathway for the production of
both dopamine and serotonin. Many other labs have made signiﬁcant
progress using NGS for rare diseases, such as the Undiagnosed Dis-
eases Program and the Centers of Mendelian Diseases [17–19]. As
turnaround time decreases, throughput increases, and computational
algorithms become more advanced, NGS has seen utility in emergent
settings, such as the neonatal intensive care unit. Kingsmore et al.
showed that turn-around time from blood draw to diagnosis can be
as fast as 50 h with the support of a well-annotated database and
algorithms [20].
Another major beneﬁt of NGS comes from the accurate sub-
classiﬁcation of diseases. Subpopulation and epigenetic dynamics
would be beneﬁcial in the area of pharmacogenomics where not
only the targeted drugs can be selected for the appropriate cancers,
but also when to give combination therapy, change therapy, and ad-
minister sequential therapies. As shown for breast cancer, under-
standing the ‘molecular taxonomy’ of a disease can help distinguish
different conditions that have common pathophysiological or mor-
phological features, yet respond to different treatments. Genetically
guided prescription of the antiretroviral drug abacavir is now the
standard of care for HIV-infected patients, and it is likely that the useof tamoxifen, clopidogrel and possibly warfarin may follow in a
population-wide manner. This would be possible through recommen-
dations by professional societies and medical governing bodies and
would require a more thorough integration of genomic data in EMR at
point-of-care [21]. Efforts in identifying pharmacogenetic biomarkers
for molecular oncology testing, such as BRAF V600E for vemurafenib
in melanoma, and EML4-ALK for crizotinib and EGFR for erlotinib and
geﬁtinib in non-small cell lung cancer, have made substantial progress
[22].
NGS has made possible the accurate detection and measurement
of cell-free DNA (cfDNA) in the maternal circulation, which includes
a signiﬁcant fraction of DNA from the fetus [23–27]. With the excep-
tion of rare cases of placental mosaicism, the numbers of fragments of
DNA from the affected chromosome in fetal trisomy 13, 18, and 21 are
slightly over-represented in the cfDNA isolated from maternal blood.
Although such differences from the baseline might be small, simulta-
neous sequencing of millions of fragments of cfDNA coupled with
powerful bioinformatics algorithms afford highly accurate differenti-
ation between normal and affected pregnancies well before the end
of the ﬁrst trimester. NGS-based non-invasive prenatal testing has ex-
perienced very rapid adoption and has been validated in clinical trials
for use in pregnancies considered to be at higher risk, such as ad-
vanced maternal age, abnormal serum screening or fetal ultrasound
results. NIPT is currently recommended by the American College of
Obstetrics and Gynecology as an informed patient choice after pretest
counseling [3]. This technology also makes it possible to detect
sex chromosome abnormalities, such as 45,XO (Turner syndrome);
47,XYY (Jacobs syndrome); 47,XXY (Klinefelter syndrome); and
47,XXX (Triple X syndrome). Studies in lower-risk populations are
ongoing, raising the possibility that NIPT could become a universal
screening test for all pregnancies.
As next-generation sequencing methods for single-cell analysis
are reﬁned, they will have the potential to displace microarrays as
the technology of choice for pre-implantation genetic screening
(PGS) applications over the next few years. Currently, the success
rate for single embryo transfer (SET) with in vitro fertilization (IVF)
is inﬂuenced by a number of factors, most notably maternal age.
Early clinical experience has shown that selection of embryos on the
basis of DNA microarray results has the potential to signiﬁcantly in-
crease implantation rates [28,29]. The use of NGS is also expected to
lead to the convergence of PGS and PGD (pre-implantation genetic
diagnosis) into a single test, performed on one or a few cells prior
to embryo implantation. PGD by traditional methods (FISH, PCR) is
currently used to test for a speciﬁc genetic abnormality (such as a cys-
tic ﬁbrosis mutation, or a micro-deletion resulting in a known clinical
syndrome) when the embryo is considered to be at high risk for that
speciﬁc abnormality on the basis of family history. In the future,
genome-wide NGS may allow for hypothesis-free testing of a wide
range of inherited disorders in the embryo. The rapid progress of
research in NIPT by NGS suggests the possibility of detecting fetal
subchromosomal abnormalities [30]. The sequencing of the entire
fetal genome from maternal blood has been recently demonstrated
[31,32], raising the possibility of using NIPT not only for chromosomal
and sub-chromosomal abnormality detection, but also for prenatal
detection of conditions with a Mendelian pattern of inheritance.
The translational utility of genomic sequencing is clear, from under-
standing of human genetic variation and its association with disease
risk and individual response to treatment, to the interpretation and
translation of the data for health-care professionals. Genome sequencing
is expected to become a central piece of routine healthcaremanagement.
NGS will be a critical technology for disease characterization and moni-
toring in molecular pathology. To further NGS applications, platform
development has been focused on longer sequence read lengths, faster
turn-around-time, and higher accuracy. Large research efforts have also
been directed to the front-end sample preparation and automation, as
well as the development of highly sensitive assays such as blood-based
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of-care, efforts to curate databases of genetic variants and their associa-
tions to drug response such as PharmGKB (http://www.pharmgkb.org/)
are facilitating this transition. Highly digitized genomic information will
likely be maintained and managed through cloud solutions to allow
for centralized databasing, data sharing, exchange, and interpretation
which will result in accurate and reliable reporting, a prerequisite for
physicians to practice genomic medicine.
In the next few years, NGS technology will likely make the repeat-
ed analysis of large number of genes or whole genome for somatic
mutation, expression and methylation routine and cost-effective.
NGS may also enable robust disease identiﬁcation using single cells
(e.g. circulating tumor or fetal cells, and cells biopsied from embryos)
or trace amounts of circulating cell-free DNA or RNA isolated from
blood or other bodily ﬂuids. Meanwhile, simultaneous measurement
of hundreds to thousands of molecular events in millions of discrete
cells will be possible with direct sequencing without (or with limited)
sample prep to enable point-of-care access. Ultimately, there will be a
much better understanding of the human genome and the causative
variations associated with complex diseases, and a more robust and
accurate informatics system to help interpret the genomic data for
clinical decisions.
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